Newswire (Published: Wednesday, November 6, 2019, Received: Wednesday, November 6, 2019, 6:53:33 PM CST)

Word Count: 426

2019 NOV 06 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, “Genomic analysis of tumor biopsy specimens is critical for precision medicine, but there are no consensus guidelines on treatment plans for specific mutations. Herein we present a case of enzalutamide-resistant prostate cancer (PC) harboring a speckle-type pox virus and zinc finger protein (SPOP) mutation with scattered allelic imbalance successfully treated using platinum-based treatment.”

Funders for this research include Ministry of Education, Culture, Sports, Science and Technology of Japan, Takeda Science Foundation, Japan.

The news reporters obtained a quote from the research from Keio University, “A 71-year-old man was diagnosed with castration-resistant PC and bone metastases. He was initial treated using enzalutamide and denosumab, and subsequently administrated radium-223. His prostate-specific antigen level initially decreased during treatment, but eventually began to rise. Magnetic resonance imaging revealed progressive PC invading the bladder, so we performed channeling transurethral resection of bladder tumor. The pathological diagnosis was adenocarcinoma with neuroendocrine differentiation. Carboplatin with etoposide therapy was initiated and no obvious tumor progression was detected thereafter. Genetic sequencing identified a SPOP p.Y87N mutation with scattered allelic imbalance. These findings suggest that enzalutamide-resistant PC with SPOP loss of function might be highly responsive to platinum-based therapy.”

According to the news reporters, the research concluded: “Mutational analyses might provide useful information for treatment guidance of refractory PC.”

For more information on this research see: Japanese Case of Enzalutamide-resistant Prostate Cancer Harboring a Spop Mutation With Scattered Allelic Imbalance: Response To Platinum-based Therapy. Clinical Genitourinary Cancer, 2019;17(5):E897-E902. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - http://www.journals.elsevier.com/clinical-genitourinary-cancer/)

Our news correspondents report that additional information may be obtained by contacting T. Kosaka, Keio University, Keio Canc Ctr, School of Medicine, Dept. of Urology, Tokyo, Japan. Additional authors for this research include K. Watanabe, H. Hongo, M. Oya, E. Aimono, H. Nishihara and S. Mikami.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clgc.2019.06.005. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Keio University

Industries

Education and Instruction
Biotechnology
      Biopharmaceuticals
            Immunotherapeutics
Pharmaceuticals
      Biopharmaceuticals
            Immunotherapeutics

Places

Eastern Asia
North America
Japan
United States
Americas
Asia
Texas
Tokyo
Dallas

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology
      Treatments and Therapies
Sports
      Amateur Sports
            College Sports